Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX ®
If approved, PREZCOBIX
®
would offer a new HIV-1 treatment option for pediatric patients aged 6 and older weighing at least 25 kg
Titusville, N.J. (June 4, 2024)
– Johnson & Johnson today announced the submission of a supplemental New Drug...
Zur Pressemeldung auf www.jnj.com